BioXcel Therapeutics
Update in progressBTAI (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
BioXcel Therapeutics, Inc., with its subsidiary OnkosXcel, is a biopharmaceutical company using artificial intelligence to develop medicines in neuroscience and immuno-oncology in the United States. Its portfolio includes IGALMI for acute agitation in adults with schizophrenia or bipolar disorder, BXCL501 (an orally dissolving dexmedetomidine) in Phase 3 for agitation, BXCL701 (oral immune activator) in early trials for various cancers, and BXCL502–504 for dementia-related symptoms. Collaborations include Columbia, Yale, and UNC. Based in New Haven, CT.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!